TripleMed BV recently announced an enrolment update regarding the pivotal clinical study of the company’s AneuFix product for the treatment of type II endoleaks. According to a TripleMed press release, 13 patients have been successfully treated with AneuFix without any major complications. The company plans to enrol a total of 25 patients across six hospitals […]
The post Pivotal study of TripleMed’s AneuFix device for type II endoleak enrols first 13 patients appeared first on Vascular News.